Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

6 September 2021

Pfizer and BioNTech Submit a Variation to EMA with the Data in Support of a Boo..

27 August 2021

Joint Communiqué: BioNTech Evaluates mRNA Vaccine Manufacturing Solutions in Rw..

26 August 2021

Pfizer and BioNTech Announce Collaboration with Brazil’s Eurofarma to Manufactu..

Press releases (more)

Upcoming Events

September 21, 2021 from 8:00 AM to 8:45 AM EDT

Berenberg and Goldman Sachs Tenth German

September 27, 2021 from 8:40 AM to 9:10 AM EDT

Cantor Virtual Global Healthcare Conference

November 9, 2021 at 8:00 AM EST

Third Quarter 2021 Earnings Call

Upcoming events (more)

Stock Quote

Sep 17, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.